Effect of infliximab on small bowel stenoses in patients with Crohn’s disease

Table 1 Main characteristics of patients and small bowel lesions on maintenance infliximab therapy

Gender	Smoker	IB	DD	Age	Previous	Associated	CDAI		FU	Infusions2	Stenosis
			(yr)	(yr)1	surgery	therapy	Inclusion	Last	months	number	Site	Number	Length (cm)	Ø (mm)	WT (mm)	PSD	Regression5
M	+	B3	11	24	3	-	74	13	26	11	PAI	1	10	5	5	-	8
M	-	B3	2.5	38	-	5-ASA	139.2	40.4	24	12	PI	1	20	7	10	+	8
M	+	B3	5.6	52	-	-	96	39.2	43	22	DI/TI	3	6	8	9	-	9
													3.5	9	6	-	22
													4.5	8	5	-	22
M	-	B2	21.5	22	1	-	28	28	54	27	PAI	1	7	9	8.5	-	6
M	+	B2	21	30	-	AZT/5-ASA	202	119	25	15	DI	1	5	4	6	+	15
F	+	B3	9	29	-	AZT/5-ASA	167	32	58	12	TI	1	5	5	7	+	12
M4	+	B2	31	21	3	-	54	28	47	223	PAI	1	7	7	6	+	-
M	-	B2	15.5	22	1	5-ASA	330.2	267.2	50	19	UGIT	4	3	4	9	+	-
													2	4	9	+	-
													6	4	9	+	-
													3	4	9	+	-
F	-	B3	30	18	3	5-ASA	241	12	51	4	PAI	1	15	9	7	+	-
M	+	B2	11	30	-	-	134.6	78.6	42	23	TI	1	25	7	9	+	-
M	-	B2	4.5	52	1	5-ASA	126	71.8	14	9	No stenosis
F	+	B3	3.2	26	-	5-ASA	154.6	0	38	9	No stenosis
M4	-	B3	5.6	19	-	-	35.6	384	24	14	No stenosis
M4	-	B3	15	38	-	5-ASA	306	144	7	6	No stenosis
F	+	B3	14.4	18	-	AZT	134	103	17	9	No stenosis

IB: Illness behavior; CDAI: CD activity index at inclusion and at the last follow-up assessment; DD: Disease duration; D: Distal ileum; F: Female; FU: Follow-up; M: Male; PAI: Pre-anastomotic ileum; PI: Proximal ileum; PSD: Prestenotic dilatation; TI: Terminal ileum; UGIT: Upper gastrointestinal tract; WT: Wall thickness;

¹Age at diagnosis;

²Some infusions were delayed for intercurrent events (e.g. pregnancy, infections etc);

³Stricturoplasty after 6 infusions of infliximab, in maintenance therapy;

⁴Patients submitted to surgery during infliximab therapy;

⁵Number of infliximab infusions at regression.